Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance
Approval is based on positive data from the Phase 3 ECHELON-3 trial
TFOS is indicated for the treatment of pulmonary arterial hypertension
Subscribe To Our Newsletter & Stay Updated